Dr. Juan Domingo Gispert presents the results of AMYPAD at an FDA seminar

On November 17, the "Quantitative Brain Amyloid PET Imaging in Patients with Alzheimer's Disease" seminar was held in Washington, organized by the Federal U.S. Food and Drug Administration (FDA), together with the Society for Nuclear Medicine and Molecular Imaging (SNMMI) and the Medical Imaging and Technology Alliance (MITA). The researcher and head of the Neuroimaging Research Group of Barcelonaβeta Brain Research Center (BBRC) Dr. Juan Domingo Gispert participated with an oral presentation on the results of the European AMYPAD project, recently completed, which has included data from our research center.

Dr. Gispert offered the exhibition "Quantitative Brain Amyloid PET Metrics", dedicated to sources of variability in quantitative metrics of positron emission tomography (PET) of amyloid. Amyloid PET allows visualization, by means of specific tracers, of accumulations of the beta amyloid protein in the brain, linked to the pathology of Alzheimer's disease. In this sense, the AMYPAD consortium has worked over the last few years to determine the diagnostic value of this test and to study how to promote the secondary prevention of the disease.

During the seminar, in which participated together with Dr. Gispert experts from institutions such as Harvard Medical School, the Imperial College of London or the University of Pittsburgh, an overview of the uses of amyloid PET in research and clinical contexts was presented. In addition, there was a debate on the clinical pharmacology of markers and quantification methodologies, among others, from perspectives from industry, commercial and professional organizations, researchers and patient support groups.